G100

BIOLOGICAL2 trials

Sponsors

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Follicular Low Grade Non-Hodgkin's LymphomaMelanomaNon-small Cell Lung CancerOvarian CancerSarcoma

Phase 1

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

TerminatedNCT02387125

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer +1

Start: 2015-02-28End: 2019-03-29Updated: 2020-07-01

Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

TerminatedNCT02501473

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Follicular Low Grade Non-Hodgkin's Lymphoma

Start: 2016-02-03End: 2019-08-01Updated: 2020-09-09

Related Papers

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Leukemia & lymphoma/Leukemia and lymphoma2021-12-0616 citations

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes

Japanese Journal of Clinical Oncology2019-06-1224 citations

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

Journal for ImmunoTherapy of Cancer2019-05-02125 citations

Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy

Annals of Oncology2018-10-011 citations

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).

Journal of Clinical Oncology2017-05-2020 citations

Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.

Journal of Clinical Oncology2017-05-202 citations

Intratumoral G100 Rescues Radiation-Induced T Cell Depletion and Has Synergistic Anti-Tumor Effect with Local Irradiation in A20 Lymphoma

Blood2016-12-021 citations

Abstract 4885: Intratumoral injection of G100 (TLR4 agonist glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity

Cancer Research2016-07-155 citations